A study to compare effectiveness for preventing disease recurrence and safety regarding drug related side effects between one month vs. two month of alternate day oral steroid in children with nephrotic syndrome, a chronic protein losing kidney disease.

Efficacy and Safety of one month vs. two month of alternate day oral steroid in managing relapse of Idiopathic Steroid Sensitive Nephrotic Syndrome

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/01/005363

Enrollment

120

Registered

2015-01-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Nephrotic Syndrome

Interventions

Intervention1: Tapering alternate day oral prednisolone: Alternate day oral prednisolone @ 1.5 mg/kg for 10 days followed by @ 1.0 mg/kg for 20 days followed by @ 0.5 mg/kg for 30 days, after achievin

Eligibility

Inclusion criteria

Inclusion criteria: Infrequent relapse nephrotic syndrome; No previously intake of any steroid sparing agent; Informed written consent.

Exclusion criteria

Exclusion criteria: Patients with severe leucopenia (leucocytes 50 IU/L), or any active infection

Design outcomes

Primary

Measure	Time frame
sustained remission at 12 monthsTimepoint: 3,6,9 and 12 month	—

Secondary

Measure	Time frame
number of relapses, cumulative steroid doseTimepoint: 3,6,9 and 12 month	—

Countries

India

Contacts

Public ContactBiswanath Basu

NRS Medical College and Hospital

basuv3000@gmail.com3323453245

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026